By Modupe Gbadeyanka
Thursday, March 8, 2018, has been fixed by the board of directors of GlaxoSmithKline Consumer Nigeria Plc for a crucial meeting to make decisions beneficial to both the company and shareholders.
At the gathering, the board will deliberate on the payment of dividend as well as the firm’s 2017 audited financial statements.
As a result, the company has announced the commencement of its closed period for dealing in its securities by the Directors, Managers or connected persons.
The closed period kicked off on Wednesday, February 21, 2018 and will terminate 24 hours after release of the result to the Nigerian Stock Exchange (NSE).
Business Post reports that during the March 8 board meeting, members will consider and approve the 2017 Audited Financial Statements, the amount to be recommended to members as dividend at the next Annual General Meeting (AGM), and fix the date and venue of the AGM.
more recommended stories
FG has not Cancelled Power Purchase Agreements—Adeosun
By Modupe Gbadeyanka Minister of Finance,.
South African Engineering Firm Eyes Nigerian, Ghanaian Markets
By Modupe Gbadeyanka Gauteng-based civil engineering.
African Steel Demand to Hit 3m Tonnes Per Year by 2050
By Modupe Gbadeyanka A new report.
Next MPC Meeting May Hold March 29—CBN Governor
By Modupe Gbadeyanka Governor of the.